sis in patients with idiopathic hypercalciuria, hyperuricosuria, or no metabolic disorder.
Liquid-Chromatographic Determination of Eight Tn-and Tetracyclic Antidepressants and Their Major Active Metabolites
Tamara A. Sutfin, Robin D'Ambrosio, and William J. Jusko A "high-performance" liquid-chromatographic method is presented for monitoring the therapeutic concentrations, in plasma, of eight tn-and tetracyclic antidepressants (amitriptyline, nortriptyline, imipramine, desipramine, doxepin, clomipramine, maprotiline, and protriptyline) and their major active metabolites. One of two internal standards is added to 0.5 mL of drug-containing plasma, the pH is adjusted to about 9.5 with borate buffer, and the sample is extracted with isoamyl alcohol in hexane. The extracts are chromatographed on a column of silica and absorbance of the effluent is measured at either 214 or 254 rim. Chromatographic response is linearly related to concentration for all components over a 5-500 ng range. Analytical recovery of the drugs and metabolites from plasma is approximately 75 to 85% at low and high concentrations. Within-run and day-to-day precision (CV) is <5% for both high arid low concentrations of most of these drugs and metabolites. Parallel analysis of clinical samples by gas chromatography indicates that results by the two techniques are comparable. We report some results of therapeutic monitoring of clinical samples. and radioimmunoassay methods of analysis for tnicyclic antidepressants. Only eight of the procedures can measure more than one antidepressant, and threefourths of the 48 chromatographic methods require 2 to 5 mL of plasma. The well-known potential problem of cross reactivity between parent drug and metabolites in RIA can be particularly significant when the metabolite exhibits a different pharmacological activity and (or) potency relative to the parent drug. More recently, at least two methods, one liquid-chromatographic and one gas-chromatographic, have been reported for simultaneous analysis for several antidepressants and metabolites (2,3). The gas-chromatographic method requires a nitrogen-sensitive detector and derivatization; the liquid-chromatographic method involves reversed-phase and requires that colunm temperature be kept high. Neither method includes the separation and identification of the active hydroxy metabolites of both amitniptyline and imipramine.
We previously reported a liquid-chromatographic method for assay of imipramine, desipramine, and their 2-hydroxy metabolites (4). This method has now been modified and extended to include the analysis of eight additional drugs and metabolites. It is applicable for therapeutic drug monitoring and for screening for toxicity in overdose cases.
Materials and Methods

Apparatus
The chromatographic system consistsof a Model 6000A 
Reagents
Stock borate buffer, pH 9.0, is prepared according to deSilva and Puglisi (5). The buffer, stored in a polyethylene bottle at 35-37 #{176}C to prevent crystallization of the salts, is prepared freshly every two months. Aliquots of the stock buffer for use in the plasma extraction procedure are adjusted to pH 10.0 with 6 molJL sodium hydroxide.
The extraction solvent consists of isoamyl alcohoLfh#{231}xane Using these, prepare three separate standard, in plasma: Standard I: amitriptyline, nortriptyline, imipramine, desipramine, 2-hydroxyimipramine, and 2-hydroxydesipramine.
Standard II: doxepin and desmethyldoxepin.
Standard III: clomipramine, desmethylclomipramine, maprotiline, and protriptyline.
Add diluted methanol solutions to drug-free, citrated human plasma to give a final concentration of each component of the calibration standards of 150 tig/mL, and of the (aqueous) controls at 30 and 300 ng/mL. Prepare the standards and controls every three months and store in polypropylene tubes at -4 #{176}C.
Extraction and Chromatographic Procedures
To 0.5-mL of each plasma-based standard, control, and unknown, in polypropylene tubes, add the appropriate internal standard, 0.5 inL of borate buffer (pH 10), and 1.5 mL of the extraction solvent. N-Desmethylclomipramine is the standard for the assay of compounds in standards I and H; desipramine is the internal standard for the compounds in standard III. Shake the mixtures for 10 mm. Using disposable glass pipets, transfer the organic layers to clean polypropylene tubes. Evaporate the extracts at ambient temperature, under nitrogen. Reconstitute each residue with 100 L of methanol and inject 50 L onto the chromatographic column. Measure the absorbance of compounds in standards I and H at 254 nm and standard ifi at 214 nm.
Flush the entire system with filtered methanol at the end ofthe analytical day. Equilibration ofthe system with fresh mobile phase requires less than 1 h.
Assay Comparisons
Serum samples containing the drugs and metabolites of interest, which had been previously assayed by the gaschromatographic method of Gupta et al. (6) , were kindly provided by Dr. R. N. Gupta (St. Josephs Hospital, Hamilton, Ontario). Since their initial analysis, the samples had been stored frozen in various types oftubes (glass, polyethylene, or polypropylene) and showed various degrees of hemolysis and lipemia. We re-analyzed these samples by the present procedure and used the weighted perpendicular least squares method (7) to correlate these results, a method that is appropriate when both variables contain experimental error.
Results and Discussion
New highly sensitive and specific liquid-chromatographic assays have enhanced the capability for routine therapeutic monitoring ofseveralantidepressant drugs and their metabolites. Our normal-phase system provides the most comprehensive assay for tri-and tetracyclic antidepressants and their major demethylated and hydroxylated metabolites to date. Figures 1 and 2 show chromatograms of extracts of the plasma-based standards and of serum from patients who had received the various antidepressants. Use of normalphase chromatography allows these antidepressants and their metabolites to be simultaneously measured. The specific metabolite patterns, characteristic of each drug, aid identification of specimens. In vitro and in vivo experimental evidence (9-11) indicatesthat the 2-hydroxy metabolites ofimipramine and desipramine, and the lO-hydroxymetabolitesof amitriptylineand nortriptylmnehave pharmacological activity. Therefore, the metabolites may contribute to the therapeutic and (or) toxic effects of the parent drugs. Results of a single-dose pharmacokinetic study of imipramine in normal volunteers predicted little accumulation of the 2-hydroxy metabolites (12). However, Potter et al. (13) reported significant concentrations in plasma of patients at steady state. Although currently there is no need to report concentrations of the hydroxy compounds, they should be resolved and distinguished from the parent drugs.
Recent reports also indicate different pharmacological potencies for the cis and trans isomers of doxepin and desmethyldoxepin (14). The demethylated metabolite of maprotiline may also be pharmacologically active, but confirmatory studies are needed.
The Zorbax Sil columns perform efficiently for at least five to six months with almost daily exposure to 1 L of mobile phase. One typicalcolumn exhibited a decrease ofonly 2.8% in relativeretention after nine months of use.
Linearity ofdetectorresponse to the amount of compound being detected, as determined by direct injection of constant volumes of methanolic solutions of each drug and metabolite, was verified over the range of 5 to 500 ng for each.
Analytical recoveries of high and low (as compared with the usual therapeutic) concentrations of drugs and metabolites from plasma ranged from 75 to 85%.
Within-run precision
(CV), based on analysis of 10 separate aliquots of plasma for each drug and metabolite, was 5% or less for most compounds. Day-to-day precision (CV), based on repeat analyses during two to three months, was <10% for all drugs and metabolites. As little as 10 ng of We examined potential interference from benzodiazepines-frequently administered with tricyclic antidepressants-by directly injecting methanolic solutions of chiordiazepoxide, diazepam, fiurazepam, and oxazepam. All the peaks associated with these compounds were eluted with the solvent front. Moreover, plasma samples from patients who were being treated with chiordiazepoxide or diazepam also showed no apparent interfering peaks. Phenothiazines are occasionally administered with tricyclic antidepressants, and they pose the greatest problem of potential interference because of their numerous and highly ultraviolet-absorbing metabolites. We analyzed several plasma samples from patients known to be taking a phenothiazine and an antidepressant. Figure if depicts a chromatogram from the plasma of a patient taking doxepin and thioridazine and exemplifies the type of pattern usually observed in these patients. Despite the cluster of unidentified peaks eluting in the middle of the chromatogram, the antidepressant concentrations can still be accurately estimated. However, the analyst should be informed about all medications that a patient is taking, so that interference from extraneous peaks can be anticipated.
We used this method on more than 100 clinical plasma samples previously analyzed elsewhere by a gas-chromato-0 3 6 9121518 0 36 91215
Time, thin Our results for 115 other samples from patients receiving these drugs, and their estimated therapeutic ranges, are shown in Figure 4 . More than half of the results fell below the therapeutic ranges; less than a quarter were within the ranges. However, the concentrations typically exceeded the minimum concentration that can be measured (10 ng/mL) and fell within the range of standards and controls (30-300 ng/mL).
Therapeutic monitoring of antidepressants has been recommended to check for compliance, to detect cases of unusu- 
